• Facebook
  • Youtube
  • Ελληνικά
  • English
Experts in Women Health Services
womana
  • HOME
  • THE DOCTOR
  • SERVICES
  • ARTICLES
  • NEWSLETTER
  • GUIDELINES
  • STUDENTS
  • CONTACT US
  • Menu Menu

Endometrial Intraepithelial Neoplasia

The American College of Obstetricians and Gynecologists

WOMEN’S HEALTH CARE PHYSICIANS

COMMITTEE OPINION

Number 631 • May 2015

Committee on Gynecologic Practice

Society of Gynecologic Oncology

This document reflects emerging clinical and scientific advances as of the date issued and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed.

Endometrial Intraepithelial Neoplasia

ABSTRACT: Endometrial hyperplasia is of clinical significance because it is often a precursor lesion to adeno­carcinoma of the endometrium. Making the distinction between hyperplasia and true precancerous lesions or true neoplasia has significant clinical effect because their differing cancer risks must be matched with an appropriate intervention to avoid undertreatment or overtreatment. Pathologic diagnosis of premalignant lesions should use criteria and terminology that clearly distinguish between clinicopathologic entities that are managed differently. At present, the endometrial intraepithelial neoplasia schema is tailored most closely to this objective, incorporating modified pathologic criteria based upon evidence that has become available since the creation of the more widely used 1994 four-class World Health Organization schema (in which atypical hyperplasia is equated with precancer­ous behavior). The accuracy of dilation and curettage compared with endometrial suction curette in diagnosing precancer and excluding concurrent carcinoma is unclear. Hysteroscopy with directed biopsy is more sensitive than dilation and curettage in the diagnosis of uterine lesions. When clinically appropriate, total hysterectomy for endometrial intraepithelial neoplasia provides definitive assessment of a possible concurrent carcinoma and effectively treats premalignant lesions. Systemic or local progestin therapy is an unproven but commonly used alternative to hysterectomy that may be appropriate for women who are poor surgical candidates or who desire to retain fertility.

Conclusions and Recommendations

Sensitive and accurate diagnosis of true premalignant endometrial lesions can reduce the likelihood of devel­oping invasive endometrial cancer. Based on avail­able data and expert opinion, the American College of Obstetricians and Gynecologists and the Society of Gynecologic Oncology make the following consensus recommendations:

  • The endometrial intraepithelial neoplasia schema seems to be preferable to the 1994 four-class World Health Organization (WHO94) schema. Pathologic diagnosis of premalignant lesions should use criteria and terminology that clearly distinguish between clinicopathologic entities that are managed differ­ently. At present, the endometrial intraepithelial neoplasia schema is tailored most closely to this objective, incorporating modified pathologic criteria based upon evidence that has become available since the creation of the more widely used WHO94 schema (in which atypical hyperplasia is equated with pre­cancerous behavior). The preferred terminology is “endometrial intraepithelial neoplasia” (rather than “atypical endometrial hyperplasia”).
  • Regarding tissue sampling, hysteroscopy, while not required, is recommended with directed dilation and curettage (D&C) to include any discrete lesions as well as the background endometrium. This will provide the best opportunity to confirm the diag­nosis of a true premalignant endometrial lesion and exclude anassociated endometrial carcinoma. When clinically appropriate, total hysterectomy for endo­metrial intraepithelial neoplasia provides definitive assessment of a possible concurrent carcinoma and effectively treats premalignant lesions.

2 Committee Opinion No. 631

Supracervical hysterectomy, morcellation, and endo­metrial ablation are unacceptable for treatment of endometrial intraepithelial neoplasia.

Systemic or local progestin therapy is an unproven but commonly used alternative to hysterectomy that may be appropriate for women who are poor surgical candidates or who desire to retain fertility.

Posthormonal treatment surveillance after nonsurgi­cal management of endometrial intraepithelial neo­plasia may include serial endometrial sampling every 3–6 months, but the appropriate frequency has not yet been determined. precancerous behavior).

*Previously known as atypical endometrial hyperplasia.

Data from Baak JP, Mutter GL, Robboy S, van Diest PJ, Uyterlinde AM, Orbo A, et al. The molecular genetics and morphometry-based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization classification system. Cancer 2005;103:2304–12 and Mutter GL. Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group. Gynecol Oncol 2000;76:287–90.

Vasilios Tanos MD PhD,
Professor of Obstetrics and Gynecology, St. George’s Medical School at the University of Nicosia and Aretaeio Hospital in Nicosia

Contact

Disclaimer

Κατευθυντήριες Οδηγίες

  • Breast Cancer Screening
  • Early detection of cervical cancer
  • Endometrial Intraepithelial Neoplasia
  • Treatment of menopausal symptoms
womana
womana

The Doctor

Vasilios Tanos MD PhD,
Professor of Obstetrics and Gynecology, St. George’s Medical School at the University of Nicosia and Aretaeio Hospital in Nicosia, Cyprus

Services

  • Preventive Medicine
  • Gynecology
  • Reproductive Medicine and Surgery
  • Obstetrics
  • List of operations

Find us

Aretaeio Hospital
55-57 Andrea Avraamides, 2024 Nicosia, Cyprus

+357 22 200 629

info@womana.com.cy

fb.com/womana.com.cy

© 2022 Dr Vasilios Tanos. All Rights Reserved. Website Designed & Developed by ECONSTRUO DIGITAL
Disclaimer | Privacy Policy
Scroll to top

By continuing to use this website, you consent to the use of cookies in accordance with our Cookie Policy.

Learn moreAccept

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, you cannot refuse them without impacting how our site functions. You can block or delete them by changing your browser settings and force blocking all cookies on this website.

Google Analytics Cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visist to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Vimeo and Youtube video embeds:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Privacy Policy